Neurocrine's Phase II schizophrenia trial fails to meet primary endpoint [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
The randomised, parallel-group, double-blind, placebo-controlled trial enrolled adults with cognitive impairment associated with schizophrenia (CIAS). It assessed the safety, efficacy and tolerability of the asset in these subjects. According to the findings, luvadaxistat did not offer improvement in cognitive impairment in schizophrenia patients in the ERUDITE study, a second Phase II trial of the asset. The study's failure to meet cognitive endpoints is said to contrast with the earlier INTERACT study's positive results, the company noted. The variability in cognitive measures and potential baseline characteristic imbalances across treatment arms have been cited as contributing factors to the latest outcomes. A selective inhibitor targeting d-amino acid oxidase (DAAO), luvadaxistat is designed to modulate NMDA receptor function in the brain, which is implicated in the cognitive deficits observed in schizophrenia. Neurocrine acquired the rights to develop and commerciali
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.MarketBeat
- Stocks making the biggest moves after hours: Adobe, RH, Oracle and more [CNBC]CNBC
- Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with SchizophreniaPR Newswire
- Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare ConferencePR Newswire
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Barclays PLC from $180.00 to $160.00. They now have an "overweight" rating on the stock.MarketBeat
NBIX
Earnings
- 8/1/24 - Beat
NBIX
Sec Filings
- 9/17/24 - Form 4
- 9/13/24 - Form 144
- 8/28/24 - Form 8-K
- NBIX's page on the SEC website